Literature DB >> 7843224

CD4 T cells inhibit in vivo the CD8-mediated immune response against murine colon carcinoma cells transduced with interleukin-12 genes.

A Martinotti1, A Stoppacciaro, M Vagliani, C Melani, F Spreafico, M Wysocka, G Parmiani, G Trinchieri, M P Colombo.   

Abstract

Retroviral-mediated cytokine gene transfer into tumor cells is a highly effective way of inducing tumor inhibition and immunity. We analyzed the tumorigenicity of C-26 murine colon carcinoma cells transduced with genes encoding the two subunits of murine interleukin-12 (IL-12) in a polycistronic retroviral vector and selected for resistance to G418 and for IL-12 production (30-80 pg/ml). BALB/c mice injected s.c., i.v. and intrasplenically with C-26/IL-12 cells from three different IL-12-producing clones showed delayed tumor onset as compared with mice injected with control NeoR-transduced or parental tumor cells. Although C-26/IL-12 tumor-bearing mice eventually died of lung metastasis, their survival time was twice as long as that of mice injected with control cells. In experiments with mice selectively depleted of natural killer (NK) cells before tumor cell injection, the time of tumor onset and survival of mice injected with C-26/IL-12 s.c. and i.v., respectively, was reduced. CD8+ T cell depletion had no effect on latency or survival, whereas removal of CD4+ T cells led to C-26/IL-12 tumor regression in about 40% of mice. Histological and immunocytochemical characterization of leukocytes infiltrating C-26/IL-12 tumors showed only slight infiltration with few T cells in non-depleted mice but abundant infiltration by CD8+ T cells and asialo-GM1+ NK cells in tumors of mice depleted of CD4+ T cells. The lack of CD8+ T cell infiltration is not due to a CD4-mediated suppression of their activation because irradiated C-26/IL-12 cells primed for the induction of a strong cytotoxic T lymphocyte response against C-26 parental cells and induced CD8+ effector cells that protected against C-26/IL-12 in a Winn assay. Rather, the results suggest that, although C-26/IL-12 cells injected in vivo stimulate both NK and CD8+ T cells, tumor infiltration by the latter is inhibited by CD4+ T cells.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7843224     DOI: 10.1002/eji.1830250124

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  15 in total

1.  Gene gun-mediated skin transfection with interleukin 12 gene results in regression of established primary and metastatic murine tumors.

Authors:  A L Rakhmilevich; J Turner; M J Ford; D McCabe; W H Sun; P M Sondel; K Grota; N S Yang
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-25       Impact factor: 11.205

2.  Antimetastatic vaccination against Lewis lung carcinoma with autologous tumor cells modified to express murine interleukin 12.

Authors:  D Popovic; K M El-Shami; E Vadai; M Feldman; E Tzehoval; L Eisenbach
Journal:  Clin Exp Metastasis       Date:  1998-10       Impact factor: 5.150

Review 3.  New insights into IL-12-mediated tumor suppression.

Authors:  S Tugues; S H Burkhard; I Ohs; M Vrohlings; K Nussbaum; J Vom Berg; P Kulig; B Becher
Journal:  Cell Death Differ       Date:  2014-09-05       Impact factor: 15.828

4.  IFN-gamma and IL-12 but not IL-10 are required for local tumour surveillance in a syngeneic model of orthotopic bladder cancer.

Authors:  J Riemensberger; A Böhle; S Brandau
Journal:  Clin Exp Immunol       Date:  2002-01       Impact factor: 4.330

5.  Adenovirus-mediated interleukin-12 gene therapy for metastatic colon carcinoma.

Authors:  M Caruso; K Pham-Nguyen; Y L Kwong; B Xu; K I Kosai; M Finegold; S L Woo; S H Chen
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-15       Impact factor: 11.205

Review 6.  Tumor cells engineered to produce cytokines or cofactors as cellular vaccines: do animal studies really support clinical trials?

Authors:  M P Colombo; M Rodolfo
Journal:  Cancer Immunol Immunother       Date:  1995-11       Impact factor: 6.968

7.  Synergistic inhibition of tumor growth in a murine mammary adenocarcinoma model by combinational gene therapy using IL-12, pro-IL-18, and IL-1beta converting enzyme cDNA.

Authors:  K Oshikawa; F Shi; A L Rakhmilevich; P M Sondel; D M Mahvi; N S Yang
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-09       Impact factor: 11.205

Review 8.  Tissue-resident cytotoxic innate lymphoid cells in tumor immunosurveillance.

Authors:  Efstathios G Stamatiades; Ming O Li
Journal:  Semin Immunol       Date:  2019-03-21       Impact factor: 11.130

9.  Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis.

Authors:  C M Coughlin; K E Salhany; M Wysocka; E Aruga; H Kurzawa; A E Chang; C A Hunter; J C Fox; G Trinchieri; W M Lee
Journal:  J Clin Invest       Date:  1998-03-15       Impact factor: 14.808

10.  Can immunotherapy by gene transfer tip the balance against colorectal cancer?

Authors:  S M Todryk; H Chong; R G Vile; H Pandha; N R Lemoine
Journal:  Gut       Date:  1998-10       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.